Cargando…

Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels

OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first po...

Descripción completa

Detalles Bibliográficos
Autores principales: Vural Topuz, Özge, Görtan, Fatma Arzu, Kaya Döner, Zübeyde Rana, Önsel, Çetin, Sayman, Haluk Burçak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996600/
https://www.ncbi.nlm.nih.gov/pubmed/29889028
http://dx.doi.org/10.4274/mirt.70783
_version_ 1783330902975184896
author Vural Topuz, Özge
Görtan, Fatma Arzu
Kaya Döner, Zübeyde Rana
Önsel, Çetin
Sayman, Haluk Burçak
author_facet Vural Topuz, Özge
Görtan, Fatma Arzu
Kaya Döner, Zübeyde Rana
Önsel, Çetin
Sayman, Haluk Burçak
author_sort Vural Topuz, Özge
collection PubMed
description OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. RESULTS: Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p<0.001) than that in patients with positive SLNBs. CONCLUSION: Our results showed that (18)F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame.
format Online
Article
Text
id pubmed-5996600
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-59966002018-06-14 Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels Vural Topuz, Özge Görtan, Fatma Arzu Kaya Döner, Zübeyde Rana Önsel, Çetin Sayman, Haluk Burçak Mol Imaging Radionucl Ther Original Article OBJECTIVE: We investigated the utility of PET/CT in cutaneous melanoma (CM) patients with pathological negative sentinel lymph nodes (SLN), within the first year. METHODS: The results of PET/CTs and SLN biopsy (SLNB) in 65 patients (39 male and 26 female, mean age 53.8) with a PET/CT in the first postoperative year were evaluated. Within this cohort, the utility of early PET/CT imaging was assessed in patients with negative SLNB. McNemar test was used to compare PET/CT findings with SLNB results. RESULTS: Out of 43 patients with pathologically positive SLNs, 23 patients (53.5%) had positive and 20 patients (46.5%) had negative findings on PET/CT within the first postoperative year. On the other hand, PET/CT results of 22 patients with negative SLNBs were found to be negative in 19 patients (86.4%) and positive in 3 patients (13.6%). For the patients with negative SLNB results, the detection rate of distant metastasis with PET/CT was significantly lower (p<0.001) than that in patients with positive SLNBs. CONCLUSION: Our results showed that (18)F-FDG PET/CT will most likely (86.4%) be negative during the first postoperative year in patients with a negative SLNB. Therefore, it is concluded that this modality would not provide any significant clinical contribution within this time frame. Galenos Publishing 2018-06 2018-06-07 /pmc/articles/PMC5996600/ /pubmed/29889028 http://dx.doi.org/10.4274/mirt.70783 Text en ©Copyright 2018 by Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Yayinevi. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Vural Topuz, Özge
Görtan, Fatma Arzu
Kaya Döner, Zübeyde Rana
Önsel, Çetin
Sayman, Haluk Burçak
Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title_full Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title_fullStr Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title_full_unstemmed Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title_short Usefulness of (18)F-FDG PET/CT in Cutaneous Melanoma Patients with Negative Sentinel Lymph Nodes and High Clark Levels
title_sort usefulness of (18)f-fdg pet/ct in cutaneous melanoma patients with negative sentinel lymph nodes and high clark levels
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996600/
https://www.ncbi.nlm.nih.gov/pubmed/29889028
http://dx.doi.org/10.4274/mirt.70783
work_keys_str_mv AT vuraltopuzozge usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels
AT gortanfatmaarzu usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels
AT kayadonerzubeyderana usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels
AT onselcetin usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels
AT saymanhalukburcak usefulnessof18ffdgpetctincutaneousmelanomapatientswithnegativesentinellymphnodesandhighclarklevels